发明名称 SULFONAMIDES
摘要 Compounds of the formula, (see formula I) wherein R1 signifies heterocyclyl; R2 signifies hydrogen, lower-alkyl, lower-alkoxy, lower-alkylthio, lower-alkoxy-lower-alkyl, lower-alkylsulphonyl-lower-alkoxy, phenyl, lower alkylphenyl, lower-alkoxy-phenyl, lower-alkylene-dioxyphenyl, phenyl-lower alkyl, lower alkyl-phenyl-lower alkyl, lower alkoxy-phenyl-lower alkyl, lower alkylenedioxyphenyl-lower alkyl, heterocyclyl or heterocyclyl-lower alkyl; R3 signifies lower-alkyl, lower-alkoxy, formyl, halo-lower-alkyl, hydroxy-lower-alkyl, amino-lower-alkyl or a residue -CH2O-A-lower-alkyl, -(CH2)m-O-(CR a R b)n OH, -(CH2)m-O-(CR a R b)n OR9, -(CH2)m-O-(CR a R b)n NH2 or -(CH2)m-O-(CR a R b)n-B-R9; R4-R8 signify hydrogen, lower-alkoxy or halogen; R9 signifies heterocyclyl; phenyl or phenyl substituted by lower-alkyl, lower-alkoxy and/or halogen, or lower-alkyl; R a and R b signify hydrogen or lower-alkyl; A signifies a ketalized 1,2-dihydroxy-ethylene group; B signifies -OC(O)O-, -O(C(O)NH-, -NH(C(O)NH- or -NHC(O)O-: n signifies 2, 3 or 4; and m signifies 0 or 1 are inhibitors for endothelin receptors. They can be used for the treatment of disorders which are associated with endothelin activities, especially circulatory disorders such as hypertension, ischaemia,vasospasms and angina pectoris.
申请公布号 CA2162630(C) 申请公布日期 2007.05.01
申请号 CA19952162630 申请日期 1995.11.10
申请人 F. HOFFMANN-LA ROCHE AG 发明人 BREU, VOLKER;BURRI, KASPAR;CASSAL, JEAN-MARIE;CLOZEL, MARTINE;HIRTH, GEORGES;LOFFLER, BERND-MICHAEL;MULLER, MARCEL;NEIDHART, WERNER;RAMUZ, HENRI
分类号 C07D239/46;C07D401/14;A61K31/4427;A61K31/505;A61K31/506;A61K31/535;A61K31/54;A61P9/00;A61P9/10;A61P9/12;A61P43/00;C07D213/00;C07D239/00;C07D239/47;C07D261/02;C07D277/02;C07D317/48;C07D333/02;C07D401/12;C07D405/12;C07D405/14;C07D409/12;C07D409/14;C07D413/12;C07D413/14;C07D417/12;C07D417/14;C07D473/00 主分类号 C07D239/46
代理机构 代理人
主权项
地址